Oncology Institute appoints Mark Pacala and Gabe Ling to Board, expanding to 9 members

Oncology Institute, Inc.

Mark Pacala brings >30 yrs healthcare management/PE experience; former CEO of Forum Group and American Whole Health.
Gabe Ling is co-founder of M33 Growth, a principal stockholder; previously partner at General Catalyst.
Appointments effective immediately; new directors will serve until 2023 Annual Meeting.
Neither director will serve on any committee; Pacala determined independent; Ling affiliated with M33.
Compensation will follow standard non-employee director policy as disclosed in 10-K.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Pacala

Director

TOI · Oncology Institute, Inc.

Effective: 2022-09-21
Filed: September 22, 2022, 7:59 PM ET

the Board appointed Mr. Mark Pacala and Mr. Gabriel Ling to the Board, effective immediately

Appointed

Gabriel Ling

Director

TOI · Oncology Institute, Inc.

Effective: 2022-09-21
Filed: September 22, 2022, 7:59 PM ET

the Board appointed Mr. Mark Pacala and Mr. Gabriel Ling to the Board, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Pacala was appointed as Director at Oncology Institute, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Mr. Mark Pacala and Mr. Gabriel Ling to the Board, effective immediately

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gabriel Ling was appointed as Director at Oncology Institute, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Mr. Mark Pacala and Mr. Gabriel Ling to the Board, effective immediately

View on SEC.gov

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-025349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.